fls.txt
Consequently, no forward-looking statement can be guaranteed.


item1.txt
 As a result of the foregoing, the Company recorded net income of $142,000 for the three months ended September 30, 2018 compared to a net loss of $232,600 for the three months ended September 30, 2017.
Consequently, no forward-looking statement can be guaranteed.
 See notes to unaudited condensed consolidated financial statements.
  Evaluation of Disclosure Controls and Procedures.
The results reflected total non-cash amounts for depreciation and amortization of $75,900 and $77,100 for the three months ended September 30, 2018 and 2017, respectively.
Net revenues for the three months ended September 30, 2018 increased $757,800 (59.2%) to $2,038,600 from $1,280,800 for the three months ended September 30, 2017, reflecting an increase of $492,500 (41.1%) in net sales of benchtop laboratory equipment.
 The fair value of the contingent consideration obligations are based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria.
 Report dated September 28, 2018 reporting under item 8.01
  Net cash provided by operating activities was $460,700 for the three months ended September 30, 2018 compared to $103,600 used during the three months ended September 30, 2017, primarily as a result of the income for the current year period.
 See notes to unaudited condensed consolidated financial statements.
Goodwill amounted to $705,300 at September 30, 2018 and June 30, 2018, all of which is expected to be deductible for tax purposes.
 General and administrative expenses for the three months ended September 30, 2018 amounted to $416,500 compared to $428,400 for the three months ended September 30, 2017 due to various minor decreases in expenses for the Bioprocessing Systems Operations and the Catalyst Research Instruments Operations.
 See notes to unaudited condensed consolidated financial statements.
  Evaluation of Disclosure Controls and Procedures.
 Research and development expenses decreased by $11,700 (9.1%) to $117,400 for the three months ended September 30, 2018 compared to $129,100 for the three months ended September 30, 2017, primarily because of reduced new product development activities in the current year period for benchtop laboratory equipment.
 In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments”.
The adoption of this ASU had no impact on the Company’s consolidated financial statements.
 The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
As of September 30, 2018, the order backlog for catalyst research instruments was $329,400, all of which is expected to be shipped during the fiscal year ending June 30, 2019, compared to $323,900 as of September 30, 2017.
Revenues derived from the Bioprocessing Systems Operations which comprise primarily of net royalties accrued from sublicensees increased by $76,500 (145.2%) to $129,200 for the three months ended September 30, 2018 compared to $52,700 for the three months ended September 30, 2017.
Sales of catalyst research instruments increased by $188,800 to $217,500 for the three months ended September 30, 2018 compared to $28,700 for the three months ended September 30, 2017 because there were no large orders shipped during the prior year period.
Cash and cash equivalents increased by $454,200 to $1,507,300 as of September 30, 2018 from $1,053,100 as of June 30, 2018.
  Overview.
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
  Forward-Looking statements.
The Company used $1,600 in financing activities in the three months ended September 30, 2018 compared to $144,300 in the three months ended September 30, 2017 due to the contingent consideration paid in the prior year period.


